HOME >> MEDICINE >> NEWS
Iressa news backgrounder: Testing of smart drug expands at M. D. Anderson Cancer Center

It is a drug suffused in promise, a next-generation therapy that has shown glimmers of powerful potential. Iressa is the kind of treatment that oncologists dream of - a pill that can be swallowed once a day, a non-toxic therapy that causes few side effects. For 10 percent of patients who have tried it, people who have no other options left for them, Iressa seems to make the difference between life and death. Another 30 percent to 40 percent of patients who have used the drug have a better, if not a longer, life.

But for most patients, Iressa does not shrink their cancer. That fact has become a challenge to researchers at The University of Texas M. D. Anderson Cancer Center. They are dedicated to solving the central puzzle that Iressa, and similar other targeted therapies, pose - what are the cancers that may best respond, and which patients will benefit?

M. D. Anderson researchers have been at the forefront of testing Iressa, as well as a slew of other experimental drugs that target critical cancer cell pathways. They have been involved in all phases of clinical trials looking at the effectiveness of Iressa in common lung cancer, work that helped lead to federal Food and Drug Administration approval of the drug in early 2003 for use when standard therapy has not helped lung cancer patients.

Now, investigators at M. D. Anderson are testing Iressa in malignant brain cancer and are poised to study it in a number of cancers, including head and neck, breast, and prostate, along with further investigations in lung cancer.

"M. D. Anderson is one of the leading institutions in developing targeted therapies such as Iressa," says Frank Fossella, M.D., professor in the Department of Thoracic/Head and Neck Medical Oncology, who has treated many lung and other head and neck cancers where it has shown tantalizing benefit.

"So far, Iressa has been a good news, bad news story. The response rates are not as high as we woul
'"/>

Contact: Laura Sussman
lsussman@mdanderson.org
713-745-2457
University of Texas M. D. Anderson Cancer Center
28-Apr-2004


Page: 1 2 3 4 5 6 7 8 9 10

Related medicine news :

1. Gene mutations predict which lung cancers will respond to Iressa
2. Iressa news backgrounder
3. Chemoprevention backgrounder: Working for a future of cancer chemoprevention
4. Cancer gene therapy news backgrounder: New ideas fuel next generation gene therapy research
5. Cancer markers news backgrounder: Future of cancer diagnosis, treatment lies in tumor barcode
6. St. Jude scientist to lead NCI Pediatric Preclinical Testing Program
7. Testing drugs ability to reverse stroke after standard three-hour window has closed
8. Testing may one day pinpoint which early-stage cancer patients are at risk for relapse
9. Testing earlier for gestational diabetes a smarter way to screen pregnant women
10. Testing for alcohol problems in the workplace
11. UNC Researchers Testing First In New Class Of AIDS Drugs

Post Your Comments:
(Date:7/3/2015)... Red Deer, Alberta (PRWEB) , ... July 03, 2015 , ... ... Camp host their 24-Hour Train-a-Thon where they provide members of the Red Deer community ... This year’s full day of fitness training, games, food, events and entertainment raised thousands ...
(Date:7/2/2015)... ... ... Following the recent report by JAMA Internal Medicine published on ... Samir Becic emphatically declared a war on obesity in the United States. , "Obesity ... must understand the magnitude of this discovery. For that reason, I am declaring, along ...
(Date:7/2/2015)... ... , ... In 2012, Patrick Achebe realized that the gift of poetry was fully in him, ... his first poem, and three years later he was publishing an entire book of poetry. ... the world. "I have always believed that the best way to lift yourself up, is ...
(Date:7/2/2015)... ... ... Six months ahead of his 80th birthday, Don Stevenson has reached the ... the Pulmonary Hypertension Association (PHA). Stevenson began the walk in Washington State three ... He left Glasgow, Mont. yesterday morning and is making his way to Wolf Point. ...
(Date:7/2/2015)... CA (PRWEB) , ... July 02, 2015 , ... ... of Dr. Divakar R. Krishnareddy, M.D., to the orthopedic and spine surgery team ... disc herniations, sprains, strains, bursitis, and tendonitis. Along with the spine and spine ...
Breaking Medicine News(10 mins):Health News:Red Deer Fitness Studio Raises $10,000 for Charity Organization with 24-Hour Train-a-Thon 2Health News:Red Deer Fitness Studio Raises $10,000 for Charity Organization with 24-Hour Train-a-Thon 3Health News:Samir Becic's Health Fitness Revolution Declares War Against Obesity in America 2Health News:Samir Becic's Health Fitness Revolution Declares War Against Obesity in America 3Health News:Samir Becic's Health Fitness Revolution Declares War Against Obesity in America 4Health News:Patrick Achebe Releases Debut Book, Whispering Waves: Poems for Everyday Grace 2Health News:79-Year-old ‘Pacing Parson’ Passes 1,000-Mile Mark in Cross-Country Walk for Pulmonary Hypertension Association 2Health News:79-Year-old ‘Pacing Parson’ Passes 1,000-Mile Mark in Cross-Country Walk for Pulmonary Hypertension Association 3Health News:Healthpointe Welcomes Dr. Divakar R. Krishnareddy to its Orthopedic Team in Anaheim 2Health News:Healthpointe Welcomes Dr. Divakar R. Krishnareddy to its Orthopedic Team in Anaheim 3
(Date:7/2/2015)... 2015 According to a new market ... Stimulation, Spinal Cord Stimulation, Transcranial Magnetic Stimulation), Application (Depression, Parkinson,s, ... 2020", published by MarketsandMarkets, the global Neuromodulation Market is estimated ... $6.20 Billion by 2020, at a CAGR of 11.2% during ... 4 market data T ables and ...
(Date:7/2/2015)... , July 2, 2015 Numotion,s Board ... Officer announced that Tamas Feitel has joined ... joins Numotion after a highly successful 18 year career ... roles driving strategy, profitability, and productivity to result in ... recent position was Chief Financial Officer for GE Healthcare ...
(Date:7/2/2015)... , June 25, 2015 ... ) has announced the addition of the ... and Immunodiagnostics: Global Challenges, Emerging Technologies, Competitive ... 2015 New Frontiers in Clinical Chemistry ... Landscape is a new seven-country strategic analysis ...
Breaking Medicine Technology:Neuromodulation Market Worth $6.20 Billion by 2020 2Neuromodulation Market Worth $6.20 Billion by 2020 3Neuromodulation Market Worth $6.20 Billion by 2020 4Numotion Names Tamas Feitel Chief Financial Officer 2New Frontiers in 2015 Global Clinical Chemistry and Immunodiagnostics Market: Challenges, Emerging Technologies, Competitive Landscape 2
Cached News: